Sangamo Therapeutics, Inc (SGMOQ) income statement
SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q1 năm tài chính 2026, quý kết thúc ngày Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 4/30
$0.10−0.01 (-8.17%)
Close on Oct 19, 2026Market cap $39.43MP/E –Yield –
Sangamo Therapeutics, Inc income statement
Ratios
Latest available, balances at Mar 31, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -357.5%
- Net margin
- -356.9%
- Return on equity, FY2025
- -2891.8%
Financial strength
- Current ratio
- 0.70
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 51.9%
Valuation
- P/E ratio
- –
- Price to sales
- 1.14
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?